Overdose deaths down 35 percent after opening of Vancouver's supervised injection site: study

April 18, 2011 in HIV & AIDS

Illicit drug overdose deaths in Vancouver's Downtown Eastside dropped by 35 per cent after the establishment of Insite, North America's first supervised injection facility, according a new study by researchers at the University of British Columbia and the British Columbia Centre for Excellence in HIV/AIDS.

Published today in The Lancet, the study is the first to assess the impact of supervised injection sites on overdose mortality. Researchers compared nearly 300 case reports from the British Columbia Coroners Service documenting all illicit drug overdose deaths in Vancouver between January 1, 2001 and December 31, 2005.

Compared to the 35 per cent reduction in overdose deaths in the immediate vicinity of Insite following its opening in September 2003, overdose deaths in the rest of Vancouver declined only nine per cent over the same period. No overdose deaths have been recorded at Insite since the facility's opening. The researchers also noted that there was no evidence of significant changes in drug supply or purity during the study period.

"This study provides the first unequivocal scientific evidence of the benefits of supervised injection facilities, and clearly demonstrates that facilities such as Insite are saving lives and playing a vital role in reducing the harms associated with ," says co-author Dr. Julio Montaner, director of the BC-CfE and Chair of AIDS Research at the UBC Faculty of Medicine.

"Research results clearly show facilities such as Insite could literally be the difference between life and death for many people," says senior author Dr. Thomas Kerr, an associate professor at UBC and co-director of the Urban Health Research Initiative (UHRI), a program of the BC-CfE.

Insite is a pilot facility with 12 injection seats in a neighbourhood with an estimated 5,000 . Currently operating at capacity, Insite staff supervise more than 500 injections on an average day. Larger reductions in overdose deaths would require an expansion of the facility.

Established in 2003 in response to an HIV epidemic and escalating overdose death rates in Vancouver's Downtown Eastside, Insite enables injection drug users to consume pre-obtained drugs under the supervision of nurses. Counsellors are also available onsite to provide support and referrals to programs, including addiction treatment. An extensive scientific evaluation by UHRI researchers has previously demonstrated the facility's ability to reduce HIV risk behaviour, increase access to addiction treatment and primary health care services, and reduce healthcare costs in the long term.

On January 15, 2010, the BC Court of Appeal upheld a decision by the BC Supreme Court and ruled that Insite, a health care facility, is under provincial jurisdiction. An earlier BC Supreme Court decision also ruled that Insite helped ensure the constitutional right to health by providing an essential health service.

The federal government has submitted an appeal to the Supreme Court of Canada. The case is scheduled to be heard on May 12, 2011. Several groups and organizations, including the Canadian Medical Association, the Canadian Public Health Association, and the Canadian Nurses Association have obtained intervener status in the upcoming Supreme Court of Canada case, and will be calling for the continued operation of Insite.

More information: The Lancet study abstract is available at http://www.cfenet. … se-mortality

Provided by University of British Columbia search and more info website

5 /5 (1 vote)  

Rank 5 /5 (1 vote)
Relevant PhysicsForums posts

More news stories

Is the U.S. ready for home HIV tests?

At the pharmacy, you can buy anything from tea kettles to Tylenol. But what if you could buy a rapid HIV test over the counter and test yourself in the privacy of your own home?

HIV & AIDS created 2 hours ago | popularity not rated yet | comments 0 | with audio podcast

Reduced glycerin formulation of tenofovir vaginal gel safe for rectal use

A change in the formulation of tenofovir gel, an anti-HIV gel developed for vaginal use, may make it safer to use in the rectum, suggests a study published online this week in the Journal of Antimicrobial Chemotherapy. In lab ...

HIV & AIDS created May 17, 2012 | popularity not rated yet | comments 0

Clergy can fight HIV on faith-friendly terms

The public health community has long struggled with how best to reduce HIV infection rates among black Americans, which is seven times that of whites. In a new paper in the journal PLoS ONE, a team of phy ...

HIV & AIDS created May 16, 2012 | popularity not rated yet | comments 0

HIV may afflict almost half Asia-Pacific transgenders: UN

Nearly half of transgender people in the Asia-Pacific region could have HIV as poor healthcare and high-risk lifestyles push infection rates to "critical levels", a UN report said Thursday.

HIV & AIDS created May 16, 2012 | popularity not rated yet | comments 0

FDA panel backs first rapid, take home HIV test

(AP) -- A panel of HIV specialists is recommending that U.S. regulators approve the first over-the-counter HIV test designed to quickly return a result in the privacy of a person's own home, a new option which could expand ...

HIV & AIDS created May 15, 2012 | popularity not rated yet | comments 0


Growth factor in stem cells may spur recovery from multiple sclerosis

A substance in human mesenchymal stem cells that promotes growth appears to spur restoration of nerves and their function in rodent models of multiple sclerosis (MS), researchers at Case Western Reserve University School ...

Use of in-hospital mortality to assess ICU performance may bias quality measurement

In-hospital mortality for ICU patients is often used as a quality measure, but discharge practices may bias results in a way that disadvantages large academic hospitals, according to a recently conducted study.

Biomarker predicts response to cancer treatment

VIB researcher Diether Lambrechts, associated with KU Leuven, has discovered a biomarker that might potentially predict which patients will benefit more from treatment with bevacizumab (Avastin). If validated, this discovery ...

Heparin-like compounds inhibit breast cancer metastasis to bone

Researchers from VTT Technical Research Centre of Finland have in collaboration with the University of Turku, Indiana University and two Finnish companies, Biotie Therapies Corp. and Pharmatest Services Ltd, discovered a ...

Stopping cell migration may help block fibrosis and the spread of cancer

(Medical Xpress) -- Discoveries by a Yale-led team of scientists could lead the way for development of new therapies for treating fibrosis and tumor metastasis. The researchers have both uncovered a signaling ...

New drug shrinks brain tumours in melanoma patients

(Medical Xpress) -- Australian researchers have reported promising results with a new drug that shrinks brain tumours in melanoma patients. Their findings are published in The Lancet medical journal today. ...